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The important work carried out by the European Centre
for Disease Control and Prevention and the World Health
Organization has demonstrated that 15 million people live
with hepatitis C and that some 86,000 people die due to
complications of this infection in the European Region
alone [1]. The scientific community has presented us with
a paradigm shift on the treatment of hepatitis C, having
transformed this chronic (and highly fatal) disease into a
curable condition. On the other hand, the high costs of
the drugs that are capable of achieving such lifesaving
results are a true challenge for health budgets worldwide.
Therefore, the parliamentary meeting organised by the
Hepatitis C European Initiative in Brussels in February
2014 was of the utmost importance. It brought together
stakeholders from different Member States of the
European Union to share experiences and knowledge,
while also reinforcing the need for us to work as a network
on solutions to the challenges we now face.
At the meeting, I took the opportunity to present the
methodology of a study on hepatitis C that I was coordi-
nating at the Catholic University of Portugal. We focused
on generating a consensus paper, which was presented on
13 May under the title: “Strategic Consensus for the
Integrated Management of Hepatitis C in Portugal.”
This consensus [2] is the result of a Portuguese “think
tank” of around 30 people chosen by a steering committee,
with representation from the realms of science, clinical
practice, health management, politics and patients. The
meeting and discussions were held between October 2013
and March 2014.
From prevention to treatment, we presented recommen-
dations based on different levels of concurrence among
think tank participants. The following recommendations
achieved the highest level of agreement:
1. International estimates [3] state that the prevalence of
hepatitis C in the Portuguese population is between 1%
and 1.5% and that around 900 to 1,200 people per year
may die due to hepatitis C complications such as cirrhosis,
hepatocellular carcinoma, HIV co-infection and non-spe-
cific liver failure.
2. Direct costs associated with hepatitis C treatment in
Portugal, mainly related to late stages of the disease, run
up to 70 million euros per year.
3. It is urgent to do more regarding hepatitis C pre-
vention. The control of the disease in the long run
depends on the reduction of new infections. There must
be an active reinforcement of risk reduction policies,
health education, and measures that limit transmission
(e.g., broadening the criteria for hepatitis C screening).
4. It is necessary to have a management and referral net-
work based on scientific criteria and subject to periodic
audits.
5. There is an urgent need for updated national proto-
cols for clinical guidance, and for these to be constantly
maintained in line with scientific developments. At the
same time, their actual use should be verified via auditing
processes.
6. The high costs associated with new therapeutic
formulations require new financing and negotiation
models (i.e., risk sharing). The aim is to ensure access to
innovation based on clinical criteria of priorities and social
justice, within the context of the Portugal National Health
Service’s financing restrictions.
7. Hepatitis C disease notification (and centralized regis-
tration) must be mandatory so that patients can have
access to the most adequate treatments.
8. The lack of up-to-date knowledge among healthcare
professionals concerning hepatitis C (and other liver
diseases) must be urgently corrected.
9. An integrated management system for hepatitis C
disease has been shown to be the most appropriate one
and therefore it is necessary to have a national action plan
and clear leadership at a central level.
In conclusion, as a society we need to find innovative
clinical, administrative and financial strategies to over-
come the budgetary barriers that limit patient access to
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life-saving treatments. To do so in a successful manner
will be a major contribution towards the sustainability of
our national health systems.
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